Publications by authors named "R D Leek"
Article Synopsis
- - Current biomarkers for assessing the risk of tumor progression in ER-negative breast cancer patients are inadequate, prompting a study on the role of the AIPL1-NUB1 pathway in tumor suppression under hypoxic conditions.
- - The study found that downregulation of AIPL1 leads to the deactivation of NUB1, observed through in vitro tests using breast cancer cell lines, and analysis of patient samples revealed significant differences in protein expression levels.
- - Ultimately, lower levels of cytoplasmic NUB1 were linked to poorer overall survival rates in patients, indicating that both NUB1 and AIPL1 may play crucial roles in the prognosis of breast cancer, particularly in ER-negative cases.
ELTD1/ADGRL4 expression is increased in the vasculature of a number of tumor types and this correlates with a good prognosis. Expression has also been reported in some tumor cells with high expression correlating with a good prognosis in hepatocellular carcinoma (HCC) and a poor prognosis in glioblastoma. Here we show that 35% of primary human breast tumors stain positively for ELTD1, with 9% having high expression that correlates with improved relapse-free survival.
View Article and Find Full Text PDFIntroduction: Liver transplant (LT) recipients have limited understanding of post-transplant chronic kidney disease (CKD) despite an excellent pre-existing framework of transplant care. This pilot study examined the efficacy and feasibility of a tailored educational and goal-setting tool in improving CKD knowledge among LT recipients with early-stage CKD.
Methods: In this prospective cohort study, we administered the CKD educational and goal-setting tool to 81 LT recipients between 7/1/2016 and 12/31/2017.
Introduction: Direct-acting antivirals (DAAs) have transformed hepatitis C virus (HCV) management post-liver transplant. As HCV clears during DAA treatment, hepatic metabolism improves, resulting in decreased tacrolimus concentrations that may require dose adjustment. The purpose of this study was to determine appropriate management of immunosuppression in liver transplant recipients during and following treatment of HCV.
View Article and Find Full Text PDF